WO1996018647A1 - Spray dried erythropoietin - Google Patents
Spray dried erythropoietin Download PDFInfo
- Publication number
- WO1996018647A1 WO1996018647A1 PCT/US1995/016416 US9516416W WO9618647A1 WO 1996018647 A1 WO1996018647 A1 WO 1996018647A1 US 9516416 W US9516416 W US 9516416W WO 9618647 A1 WO9618647 A1 WO 9618647A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rhepo
- spray
- drying
- dried
- solution
- Prior art date
Links
- 239000007921 spray Substances 0.000 title claims abstract description 36
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title description 13
- 102000003951 Erythropoietin Human genes 0.000 title description 10
- 108090000394 Erythropoietin Proteins 0.000 title description 10
- 229940105423 erythropoietin Drugs 0.000 title description 10
- 238000000034 method Methods 0.000 claims abstract description 34
- 239000000843 powder Substances 0.000 claims abstract description 13
- 238000001035 drying Methods 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 26
- 239000000243 solution Substances 0.000 claims description 22
- 238000009472 formulation Methods 0.000 claims description 21
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000007864 aqueous solution Substances 0.000 claims description 15
- 239000004471 Glycine Substances 0.000 claims description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 8
- 229930195725 Mannitol Natural products 0.000 claims description 8
- 239000000594 mannitol Substances 0.000 claims description 8
- 235000010355 mannitol Nutrition 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims 1
- 238000001694 spray drying Methods 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- 239000007787 solid Substances 0.000 description 10
- 239000008215 water for injection Substances 0.000 description 10
- 238000004108 freeze drying Methods 0.000 description 9
- 238000000502 dialysis Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000001262 western blot Methods 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 6
- 238000000889 atomisation Methods 0.000 description 5
- 239000012527 feed solution Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 238000005352 clarification Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 239000007979 citrate buffer Substances 0.000 description 3
- 150000001860 citric acid derivatives Chemical class 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000012430 stability testing Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- 150000001720 carbohydrates Chemical group 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 102000044890 human EPO Human genes 0.000 description 2
- 229920001600 hydrophobic polymer Polymers 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012792 lyophilization process Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 238000001159 Fisher's combined probability test Methods 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000473945 Theria <moth genus> Species 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
Definitions
- This invention concerns a method for the preparation of spray dried erythropoietin and the dry erythropoietin powder produced thereby.
- Erythropoietin is a glycoprotein hormone primarily synthesized in the kidney and is the chief regulator of red blood cell production in the body.
- Commercially available human EPO is produced via recombinant DNA techniques and is known as recombinant human EPO (rhEPO).
- rhEPO has a molecular mass of approximately 36,000 Daltons, as determined by SDS-PAGE.
- the molecular mass of the protein backbone is 18,398 Daltons, which indicates that the entire molecule is heavily glycolsylated.
- the carbohydrate residues are important for in vivo biologic activity.
- Maintaining proteins, such as rhEPO, in their native state in aqueous solution or in solid phase is a major challenge to those working in the field of pharmaceutical formulations.
- the existence of a protein in its native state depends on protein concentration, temperature and nature of solvent, ionic strength of the buffer, etc. Changes in any of these parameters can affect the stability of a protein in solution or solid phase.
- rhEPO rhEPO
- dilute aqueous solutions or in a lyophilized form which is used to form a dilute aqueous solution, both of which are administered to the body by injection.
- concentration of rhEPO in these preparations is very low and the rhEPO is cleared from the body fairly quickly after administration.
- concentrated preparations of rhEPO e.g., those containing higher amounts of rhEPO, which can be used in alternate drug delivery systems. We used spray drying techniques to prepare such preparations.
- Spray drying is known in the art. For example, see Broadhead, J. et al., "The Spray Drying of Pharmaceuticals," in Drug Dev. Ind. Pharm, 18 (11 & 12), 1169-1206 (1992).
- a variety of biological materials have been spray dried and these include: enzymes, sera, plasma, micro-organisms and yeasts.
- Spray drying is a useful technique because it can convert a liquid pharmaceutical preparation into a fine, dustless or agglomerated powder in a one-step process. The basic technique comprises the following four steps:
- the present invention provides a method for producing an rhEPO powder from bulk rhEPO wherein the powder produced is pure or essentially pure rhEPO or has a higher percentage (w/w) of rhEPO than can be prepared using traditional lyophilization techniques.
- the present invention provides a method for preparing stable, spray dried rhEPO and the rhEPO powder produced thereby.
- the method of the present invention comprises first providing an aqueous solution of rhEPO having a concentration within the range of about 20 mg/ml to about 100 mg/ml. That solution is then atomized into a spray and the spray is dried with hot air in order to evaporate the water from the spray. The dried rhEPO produced thereby is then separated from the drying air.
- the initial aqueous solution may contain, in addition to rhEPO, excipients such as mannitol, glycine and/or a surfactant.
- the dry rhEPO composition produced by the method of the present invention comprises rhEPO in a concentration within the range of 4.0% to 100% (w/w) and has a residual moisture content within the range of about 3.0% to about 5.0% (w/w).
- the size of the particles of the composition are within the range of about 2.0 microns to about 6.0 microns.
- a concentrated rhEPO solution of at least 20 g/ml was used for spray drying.
- the concentrated aqueous solution was atomized into fine droplets by pumping it through a nozzle with pressurized air.
- the droplets then entered a drying chamber and the wat r was evaporated by the hot drying air flowing co-current with the feed solution, AS tne water evaporated, solid rhEPO and excipients, if present, separated from the aqueous droplets.
- the dried rhEPO was carried by the drying air current to a cyclone separator for clarification, i.e., the dried rhEPO was separated from the drying air, and the dried product was collected in the collection vessel attached at the bottom of the cyclone separator. The drying air was then expelled through a fines scrubber into the atmosphere.
- rhEPO means any protein having all or part of the polypeptide backbone described for rhEPO in U.S. 4,703,008 and which possesses the biological property of causing bone marrow cells to increase production of reticulocytes and red blood cells and to increase hemoglobin synthesis or iron uptake. It is contemplated that biologically active fragments, analogs or chemically synthesized derivatives of EPO may be used in the present invention, rather than rhEPO, provided that such fragments or derivatives retain the biological activity of rhEPO. Certain EPO analogs are described in U.S. 4,703,008. Therefore, use of such biologically active EPO analogs, fragments, or derivatives is considered to be within the scope of the present invention.
- the concentrated rhEPO powders produced by the present invention may be used in alternate drug delivery systems to deliver the rhEPO.
- One such system is a controlled release delivery system that delivers the rhEPO at a predetermined rate for a definite time period in the body.
- the concentrated rhEPO powders may be reconstituted with water for injection or normal saline to form aqueous solutions suitable for human therapeutic use.
- the controlled release systems mentioned above are envisioned to include rhEPO placed within a polymeric material, vesicles or a miniature pump, as well as macromolecular conjugates of rhEPO and other polymeric materials. These systems may then be used as subdermal reservoir implants of concentrated rhEPO.
- Non-limiting examples of these systems include matrices of solid hydrophobic polymers surrounding the rhEPO, such as non-degradable ethylene-vinylacetate copolymers or degradable lactic acid-glycolic acid copolymers. Such hydrophobic polymers may additionally take the form of microspheres.
- the present invention provides stable rhEPO powder.
- stable means that the rhEPO maintains its biological activity over time and its structure is maintained in its native state, i.e. it is not oxidized or otherwise degraded into another chemical species. Stability can be substantiated by RIA, Western Blot and in vivo or in vitro bioassays.
- This example describes a process of spray drying used to produce amorphous rhEPO exclusively in solid form or in conjunction with inert, pharmaceutically acceptable excipients.
- the so formulated amorphous bulk rhEPO is stable for at least 6 months at 5°C storage (refrigerator).
- T e current literature describing spray drying of therapeutic proteins is limited and does not discuss the stability of therapeutic proteins in the dried form at higher concentrations, such as 25% (w/w) and greater. For example, see Mumenthaler et al., Pharm. Res. ⁇ :12-20 (1994). Furthermore, the current literature does not provide sufficient evidence of the stability of these proteins in the solid form.
- the spray drying process consisted of the following steps:
- Aqueous rhEPO solution was fed to the atomizer nozzle (0.5 mm I.D.) at room temperature using a peristaltic pump.
- the liquid feed was atomized into small droplets by high pressure air. Such atomization can also be achieved by using a rotating disc.
- the drying air As the droplets entered the evaporation chamber (105 mm I.D. x 450 mm L), water was evaporated by the hot drying air flowing co- current. The temperature of the drying air varied from 64-80°C. As the water evaporated, the solid separated from the aqueous solution in the shape of spheres or semi-spheres. The drying can also be performed by counter-current technique, where the drying air and the feed solution flow in the opposite direction.
- the dried powder was carried by the drying air current to a cyclone separator for clarification.
- the dried solid mass was separated from the drying air.
- the dried product was collected in a collection vessel attached at the bottom of the cyclone separator.
- the drying air (without the dried product) was expired through a fines scrubber into the atmosphere.
- Each blot contained a standard rhEPO, standard rhEPO containing a known amount of rhEPO aggregates and test sample(s). The intensity of the rhEPO standard, and aggregate standard was compared with the test sample.
- a known amount of spray dried rhEPO was reconstituted in water for injection.
- the biological activity of tin is solution was measured by monitoring the rate of incorporation of iron in exny ⁇ xit; mice after injecting the rhEPO solution.
- the method used was that of Cotes et al., Nature, 121:1065-1067 (1961).
- Formulation No. II was spray dried at two different inlet temperatures of 64 and 80°C.
- Solution feed rate 1 mL/min Air atomization rate: 600-700 normliter/hr. Drying air rate: 32,000 to 45,000 liter/hr. Inlet temperature: 64-80°C Outlet temperature: 46-65°C
- the final solid rhEPO content for formulations I and II was approx. 4% (w/w)
- formulation III was 100% w/w
- formulations IV and V were 25% (w/w) rhEPO.
- the residual moisture content varied from 3.0% to 5.0% (w/w) as determined by the Karl-Fisher method (USP XXIII-NF XVII, pp. 1840-18 ⁇ 3, method la (1995)).
- the particle size was 4.1 microns ⁇ 1.89 for spray dried formulation III.
- Tween® 80 was not necessary to produce stable spray dried rhEPO by comparing stability data on formulations I and II and formulations IV and V. Also, 6 month stability data on pure rhEPO suggests that mannitol and/or glycine may not be necessary for producing stable spray dried rhEPO. Thus, if used, mannitol and glycine merely seem to serve the function of bulking agents (as isotonic/isosmotic adjusting agents) that can be used to alter rhEPO concentration in the final spray dried rhEPO formulation.
- bulking agents as isotonic/isosmotic adjusting agents
- the spray dried rhEPO of the present invention has advantages over lyophilized rhEPO.
- formulations I, II and III were also lyophilized (see Example 2).
- RIA data for the lyophilized samples stored for 2 months at 5°C ranged from 73-78% of the label claim (LC).
- These low EPO potency values (as determined by RIA) at such a short storage duration indicate instability.
- the 6 month lyophilized samples showed more than 2% EPO aggregates on SDS-PAGE after reconstitution. This indicates instability of the reconstituted rhEPO.
- spray dried formulations were more stable than freeze dried formulations of the same composition.
- the example describes a process of lyophilization used to produce dried rhEPO in pure form or with a combination of pharmaceutically acceptable excipients.
- the stability of the rhEPO which was lyophilized was determined and the results are presented below. All of the rhEPO preparations used in this example were also spray dried as described above. The RIA and Western Blot procedures were performed essentially as described above for the spray dried rhEPO example.
- a typical lyophilization cycle for freeze drying rhEPO solutions without excipients began by freezing the solution to about -40° C and holding at that temperature for about three hours lo ensure that the solution was completely frozen. As the solution was ucmg ⁇ .u * . .. ⁇ condenser temperature was lowered to about -50° C . The primary drying was carried out by first lowering the pressure in the drying chamber to about 200 millitorr, and the system was allowed to stablize for about three hours. The temperature was then raised to about -30° C at the rate of about 0.1° C per minute. The drying (by subliming ice to water vapor) was continued for about 60 hours.
- Secondary drying was performed by raising the temperature of the product to about 15° C at the rate of about 0.5° C per minute. The pressure in the drying chamber was further reduced from about 200 millitorr to about 100 millitorr. The secondary drying phase was continued for about 16 hours to ensure complete drying. Following the secondary drying, the vials were capped and sealed. The sealed vials were stored at about 5° C until being removed for stability testing described below. For stability testing, the contents of the vial was reconstituted with water, and analyzed by RIA and Western Blot. The results of the stability testing were compiled as a percentage of rhEPO remaining. Lower percentages of rhEPO remaining demonstrate poor stability.
- the data shown in Table 4 demonstrated that lyophilized rhEPO does not remain as stable as spray dried rhEPO. Therefore, spray drying of rhEPO produces a more stable product compared witn lyophilization.
- the present invention therefore provides stable spray dried rhEPO which can be prepared without the addition of any excipients or stabilizers, such as cyclodextrins, glycine, mannitol or Tween 80.
- An excipient-free preparation of rhEPO is desirable for certain drug delivery systems, such as delivery by pulmonary route, that usually require the drug to be as free from excipients as possible.
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU9800996A HU222370B1 (en) | 1994-12-16 | 1995-12-15 | Spray dried erythropoietin |
CA2207615A CA2207615C (en) | 1994-12-16 | 1995-12-15 | Spray dried erythropoietin |
DK95943452.3T DK0805822T4 (en) | 1994-12-16 | 1995-12-15 | Spray-dried erythropoietin |
NZ298981A NZ298981A (en) | 1994-12-16 | 1995-12-15 | Preparation of spray dried erythropoietin |
AU44713/96A AU697287B2 (en) | 1994-12-16 | 1995-12-15 | Spray dried erythropoietin |
AT95943452T ATE265468T1 (en) | 1994-12-16 | 1995-12-15 | SPRAY DRIED ERYTHROPOIETIN |
EP95943452A EP0805822B2 (en) | 1994-12-16 | 1995-12-15 | Spray dried erythropoietin |
DE69532970T DE69532970T3 (en) | 1994-12-16 | 1995-12-15 | SPRAY-DRYED ERYTHROPOIETIN |
JP51929496A JP4039686B2 (en) | 1994-12-16 | 1995-12-15 | Spray dried erythropoietin |
US08/894,023 US6001800A (en) | 1994-12-16 | 1996-12-15 | Spray dried erythropoietin |
NO19972725A NO319895B1 (en) | 1994-12-16 | 1997-06-13 | Process for preparing spray-dried rhEPO, as well as dry rhEPO made according to this method and composition thereof. |
FI972557A FI119723B (en) | 1994-12-16 | 1997-06-16 | Spray-dried erythropoietin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35794794A | 1994-12-16 | 1994-12-16 | |
US08/357,947 | 1994-12-16 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US35794794A Continuation-In-Part | 1994-12-16 | 1994-12-16 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/415,726 Continuation US6235710B1 (en) | 1994-12-16 | 1999-10-12 | Spray dried erythropoietin |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996018647A1 true WO1996018647A1 (en) | 1996-06-20 |
Family
ID=23407689
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/016416 WO1996018647A1 (en) | 1994-12-16 | 1995-12-15 | Spray dried erythropoietin |
Country Status (19)
Country | Link |
---|---|
US (2) | US6001800A (en) |
EP (1) | EP0805822B2 (en) |
JP (1) | JP4039686B2 (en) |
CN (1) | CN1117762C (en) |
AT (1) | ATE265468T1 (en) |
AU (1) | AU697287B2 (en) |
CA (1) | CA2207615C (en) |
DE (1) | DE69532970T3 (en) |
DK (1) | DK0805822T4 (en) |
ES (1) | ES2219672T5 (en) |
FI (1) | FI119723B (en) |
HU (1) | HU222370B1 (en) |
IL (1) | IL116085A (en) |
NO (1) | NO319895B1 (en) |
NZ (1) | NZ298981A (en) |
PT (1) | PT805822E (en) |
TW (1) | TW425287B (en) |
WO (1) | WO1996018647A1 (en) |
ZA (1) | ZA9510708B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7172999B2 (en) | 1995-10-25 | 2007-02-06 | Roche Diagnostics Gmbh | Method and preparations for stabilizing biological materials by drying methods without freezing |
JP2010163456A (en) * | 1997-11-03 | 2010-07-29 | Roche Diagnostics Gmbh | Process for production of amorphous product by convection drying |
US8575332B2 (en) | 2003-11-14 | 2013-11-05 | Chugai Seiyaku Kabushiki Kaisha | Crosslinked polysaccharide microparticles and method for their preparation |
US9187410B2 (en) | 2009-01-23 | 2015-11-17 | Hovione Inter Limited | Process for isolating tigecycline and tigecycline made therefrom |
US9610301B2 (en) | 2008-01-15 | 2017-04-04 | Abbvie Deutschland Gmbh & Co Kg | Powdered protein compositions and methods of making same |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6542481B2 (en) | 1998-06-01 | 2003-04-01 | Tantivy Communications, Inc. | Dynamic bandwidth allocation for multiple access communication using session queues |
US6081536A (en) | 1997-06-20 | 2000-06-27 | Tantivy Communications, Inc. | Dynamic bandwidth allocation to transmit a wireless protocol across a code division multiple access (CDMA) radio link |
US6151332A (en) | 1997-06-20 | 2000-11-21 | Tantivy Communications, Inc. | Protocol conversion and bandwidth reduction technique providing multiple nB+D ISDN basic rate interface links over a wireless code division multiple access communication system |
US7936728B2 (en) | 1997-12-17 | 2011-05-03 | Tantivy Communications, Inc. | System and method for maintaining timing of synchronization messages over a reverse link of a CDMA wireless communication system |
US7496072B2 (en) | 1997-12-17 | 2009-02-24 | Interdigital Technology Corporation | System and method for controlling signal strength over a reverse link of a CDMA wireless communication system |
US7394791B2 (en) | 1997-12-17 | 2008-07-01 | Interdigital Technology Corporation | Multi-detection of heartbeat to reduce error probability |
US6222832B1 (en) | 1998-06-01 | 2001-04-24 | Tantivy Communications, Inc. | Fast Acquisition of traffic channels for a highly variable data rate reverse link of a CDMA wireless communication system |
US9525923B2 (en) | 1997-12-17 | 2016-12-20 | Intel Corporation | Multi-detection of heartbeat to reduce error probability |
US8134980B2 (en) | 1998-06-01 | 2012-03-13 | Ipr Licensing, Inc. | Transmittal of heartbeat signal at a lower level than heartbeat request |
US7773566B2 (en) | 1998-06-01 | 2010-08-10 | Tantivy Communications, Inc. | System and method for maintaining timing of synchronization messages over a reverse link of a CDMA wireless communication system |
US6526034B1 (en) | 1999-09-21 | 2003-02-25 | Tantivy Communications, Inc. | Dual mode subscriber unit for short range, high rate and long range, lower rate data communications |
AU3673001A (en) | 2000-02-07 | 2001-08-14 | Tantivy Communications, Inc. | Minimal maintenance link to support synchronization |
US8155096B1 (en) | 2000-12-01 | 2012-04-10 | Ipr Licensing Inc. | Antenna control system and method |
US7551663B1 (en) | 2001-02-01 | 2009-06-23 | Ipr Licensing, Inc. | Use of correlation combination to achieve channel detection |
US6954448B2 (en) | 2001-02-01 | 2005-10-11 | Ipr Licensing, Inc. | Alternate channel for carrying selected message types |
RU2317086C2 (en) * | 2001-02-02 | 2008-02-20 | Орто-Макнейл Фармасьютикал, Инк. | Treatment of neurological dysfunction by using fructopyranose and erythropoietin sulfamates |
EP2479905B1 (en) | 2001-06-13 | 2017-03-15 | Intel Corporation | Method and apparatuses for transmittal of heartbeat signal at a lower level than heartbeat request |
CA2498319A1 (en) * | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
US20050053666A1 (en) * | 2002-12-31 | 2005-03-10 | Stelios Tzannis | Antibody-containing particles and compositions |
KR20070090023A (en) | 2004-12-22 | 2007-09-04 | 암브룩스, 인코포레이티드 | Modified human growth hormone |
DK2399893T3 (en) | 2004-12-22 | 2018-10-08 | Ambrx Inc | COMPOSITIONS CONTAINING, INVOLVING PROCEDURES, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES |
WO2007059312A2 (en) | 2005-11-16 | 2007-05-24 | Ambrx, Inc. | Methods and compositions comprising non-natural amino acids |
JP5840345B2 (en) | 2006-09-08 | 2016-01-06 | アンブルックス, インコーポレイテッドAmbrx, Inc. | Modified human plasma polypeptides or modified human Fc scaffold proteins and uses thereof |
EP2120998B1 (en) | 2006-11-28 | 2013-08-07 | HanAll Biopharma Co., Ltd. | Modified erythropoietin polypeptides and uses thereof for treatment |
US8012931B2 (en) | 2007-03-30 | 2011-09-06 | Ambrx, Inc. | Modified FGF-21 polypeptides and their uses |
CA2685596A1 (en) | 2007-05-02 | 2008-11-13 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
PE20110426A1 (en) | 2008-07-23 | 2011-07-01 | Ambrx Inc | MODIFIED BOVINE G-CSF POLYPEPTIDES |
SG181769A1 (en) | 2009-12-21 | 2012-07-30 | Ambrx Inc | Modified porcine somatotropin polypeptides and their uses |
CA2784793A1 (en) | 2009-12-21 | 2011-07-21 | Ambrx, Inc. | Modified bovine somatotropin polypeptides and their uses |
AR083006A1 (en) | 2010-09-23 | 2013-01-23 | Lilly Co Eli | FORMULATIONS FOR THE STIMULATING FACTOR OF COLONIES OF GRANULOCITS (G-CSF) BOVINE AND VARIANTS OF THE SAME |
TW201309346A (en) | 2011-01-05 | 2013-03-01 | Hospira Inc | Spray drying vancomycin |
WO2013126552A1 (en) | 2012-02-21 | 2013-08-29 | Auburn University | Buprenorphine nanoparticle composition and methods thereof |
CN104043104B (en) | 2013-03-15 | 2018-07-10 | 浙江创新生物有限公司 | The spray dried powder and its industrialized process for preparing of hydrochloric vancomycin |
CN114805532A (en) | 2014-10-24 | 2022-07-29 | 百时美施贵宝公司 | Modified FGF-21 polypeptides and uses thereof |
CN104984323B (en) * | 2015-06-12 | 2018-05-01 | 北京四环生物制药有限公司 | Injection Recombinant Human Erythropoietin freeze drying powder injection |
CN105311624A (en) * | 2015-11-23 | 2016-02-10 | 哈药集团生物工程有限公司 | Pharmaceutical composition containing recombinant human erythropoietin |
FI3849614T3 (en) | 2018-09-11 | 2024-02-08 | Ambrx Inc | Interleukin-2 polypeptide conjugates and their uses |
US20220009986A1 (en) | 2018-10-19 | 2022-01-13 | Ambrx, Inc. | Interleukin-10 polypeptide conjugates, dimers thereof, and their uses |
KR20210136014A (en) | 2019-02-12 | 2021-11-16 | 암브룩스, 인코포레이티드 | Compositions, methods and uses thereof containing antibody-TLR agonist conjugates |
AU2021233909A1 (en) | 2020-03-11 | 2022-09-29 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and methods of use thereof |
CA3190606A1 (en) | 2020-08-20 | 2022-02-24 | Ambrx, Inc. | Antibody-tlr agonist conjugates, methods and uses thereof |
KR20240004342A (en) | 2021-04-03 | 2024-01-11 | 암브룩스, 인코포레이티드 | Anti-HER2 antibody-drug conjugates and uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0178665A2 (en) * | 1984-10-18 | 1986-04-23 | Chugai Seiyaku Kabushiki Kaisha | Stable erythropoietin preparation and process for formulating the same |
EP0613683A1 (en) * | 1993-02-04 | 1994-09-07 | Amgen Inc. | Pharmaceutical compositions for systemic administration of erythropoietin via the respiratory system |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57149228A (en) * | 1981-03-11 | 1982-09-14 | Ajinomoto Co Inc | Novel erythropoietin and its preparation |
DE3729863A1 (en) * | 1987-09-05 | 1989-03-16 | Boehringer Mannheim Gmbh | STABILIZED ERYTHROPOIETIN LYOPHILISATES |
GB9001987D0 (en) * | 1990-01-29 | 1990-03-28 | Janssen Pharmaceutica Nv | Improved cyclodextrin based erythropietin formulation |
-
1995
- 1995-11-21 IL IL11608595A patent/IL116085A/en not_active IP Right Cessation
- 1995-12-15 DK DK95943452.3T patent/DK0805822T4/en active
- 1995-12-15 PT PT95943452T patent/PT805822E/en unknown
- 1995-12-15 JP JP51929496A patent/JP4039686B2/en not_active Expired - Lifetime
- 1995-12-15 NZ NZ298981A patent/NZ298981A/en not_active IP Right Cessation
- 1995-12-15 ZA ZA9510708A patent/ZA9510708B/en unknown
- 1995-12-15 DE DE69532970T patent/DE69532970T3/en not_active Expired - Lifetime
- 1995-12-15 AT AT95943452T patent/ATE265468T1/en active
- 1995-12-15 ES ES95943452T patent/ES2219672T5/en not_active Expired - Lifetime
- 1995-12-15 CN CN95197638.9A patent/CN1117762C/en not_active Expired - Lifetime
- 1995-12-15 CA CA2207615A patent/CA2207615C/en not_active Expired - Lifetime
- 1995-12-15 WO PCT/US1995/016416 patent/WO1996018647A1/en active IP Right Grant
- 1995-12-15 EP EP95943452A patent/EP0805822B2/en not_active Expired - Lifetime
- 1995-12-15 AU AU44713/96A patent/AU697287B2/en not_active Expired
- 1995-12-15 HU HU9800996A patent/HU222370B1/en active IP Right Grant
-
1996
- 1996-06-06 TW TW085106816A patent/TW425287B/en not_active IP Right Cessation
- 1996-12-15 US US08/894,023 patent/US6001800A/en not_active Expired - Lifetime
-
1997
- 1997-06-13 NO NO19972725A patent/NO319895B1/en not_active IP Right Cessation
- 1997-06-16 FI FI972557A patent/FI119723B/en not_active IP Right Cessation
-
1999
- 1999-10-12 US US09/415,726 patent/US6235710B1/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0178665A2 (en) * | 1984-10-18 | 1986-04-23 | Chugai Seiyaku Kabushiki Kaisha | Stable erythropoietin preparation and process for formulating the same |
EP0613683A1 (en) * | 1993-02-04 | 1994-09-07 | Amgen Inc. | Pharmaceutical compositions for systemic administration of erythropoietin via the respiratory system |
Non-Patent Citations (1)
Title |
---|
MUMENTHALER M. ET AL.: "Feasibility Study on Spray-Drying Protein Pharmaceuticals : Recombinant Human Gowth Hormone and Tissue-Type Plasminogen Activator", PHARMACEUTICAL RESEARCH, vol. 11, no. 1, January 1994 (1994-01-01), pages 12 - 20, XP002000767 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7172999B2 (en) | 1995-10-25 | 2007-02-06 | Roche Diagnostics Gmbh | Method and preparations for stabilizing biological materials by drying methods without freezing |
JP2010163456A (en) * | 1997-11-03 | 2010-07-29 | Roche Diagnostics Gmbh | Process for production of amorphous product by convection drying |
US8575332B2 (en) | 2003-11-14 | 2013-11-05 | Chugai Seiyaku Kabushiki Kaisha | Crosslinked polysaccharide microparticles and method for their preparation |
US9610301B2 (en) | 2008-01-15 | 2017-04-04 | Abbvie Deutschland Gmbh & Co Kg | Powdered protein compositions and methods of making same |
US9187410B2 (en) | 2009-01-23 | 2015-11-17 | Hovione Inter Limited | Process for isolating tigecycline and tigecycline made therefrom |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU697287B2 (en) | Spray dried erythropoietin | |
US5096885A (en) | Human growth hormone formulation | |
US5589167A (en) | Excipient stabilization of polypeptides treated with organic solvents | |
KR960009929B1 (en) | Stabilized erythropoietin preparation | |
US7235253B2 (en) | Powder containing physiologically active peptide | |
KR100705997B1 (en) | Lyophilized HGF preparations | |
MXPA03004880A (en) | Stable, aerosolizable suspensions of proteins in ethanol. | |
IE64738B1 (en) | Stabilized gonadotropin containing preparations | |
EP0869816B1 (en) | Dry compositions comprising hydrophobic stabilizers | |
CA2234724A1 (en) | Stable pharmaceutical forms of administration containing parathyroid hormone | |
US6951842B2 (en) | Compositions providing for increased IGF-I solubility | |
AU768882B2 (en) | Sustained release salts of pharmaceutically active peptides and their production | |
JPH05306235A (en) | Stabilized composition of parathyroid hormones | |
MXPA97004504A (en) | Aspected eritropoyetin | |
EP1028748A1 (en) | Compositions providing for increased igf-i solubility | |
MXPA01000105A (en) | Microparticle formulation for inhalation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 95197638.9 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2207615 Country of ref document: CA Ref document number: 2207615 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 298981 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1997/004504 Country of ref document: MX Ref document number: 972557 Country of ref document: FI |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995943452 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1995943452 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08894023 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995943452 Country of ref document: EP |